SRX Health Solutions Q3 sales rise on Halo strength
SRXH•Outlook
- The company said it will focus on phased deployment of the EMJX digital-asset treasury strategy and commercialization.
- SRX plans to allocate capital to support Halo revenue growth, margin expansion and business optimization.
- The company also plans selective investments in technology, fintech, biotech, and critical infrastructure based on risk-adjusted returns.
Overview
- SRX Health Solutions' fiscal Q3 sales rose 27% year over year.
- Adjusted EBITDA loss for fiscal Q3 improved 35% year over year to $1.6 million.
- The company approved a 10 million share repurchase and declared a one-time $0.05 per share dividend.
Result drivers and key details
- Halo operations - The company said improved fill rates and record Prime Day performance at Halo contributed to sales growth.
- EMJX acquisition - The company completed the acquisition of EMJX and began integrating its AI-driven investment models.
- - The company recognized a loss from changes in fair value of digital assets, partly offset by gains in equity securities and derivative liabilities.
